{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:45:44Z","timestamp":1788749144571,"version":"build-2803163510"},"reference-count":35,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T00:00:00Z","timestamp":1418169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec id=\"S0924270814000398_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>We investigated whether the nitric oxide (NO) precursor,<jats:sc>l<\/jats:sc>-arginine, can prevent the antidepressant-like action of the fast-acting antidepressant, ketamine, in a genetic rat model of depression, and\/or induce changes in the glutamate (Glu)\/<jats:italic>N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate receptor (NMDAR)\/NO\/cyclic guanosine monophosphate (cGMP) signalling pathway. Hereby it was evaluated whether the NO signalling system is involved in the antidepressant mechanism of ketamine.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000398_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Flinders sensitive line (FSL) rats received single i.p. injections of ketamine (15 mg\/kg) with\/without pre-treatment (30 min prior) with<jats:sc>l-<\/jats:sc>arginine (500 mg\/kg). Depression-like behaviour was assessed in the forced swim test (FST) in terms of immobility, and the activation state of the Glu\/NMDAR\/NO\/cGMP pathway was evaluated<jats:italic>ex vivo<\/jats:italic>in the frontal cortex and hippocampus regions in terms of total constitutive NOS (cNOS) activity and cGMP concentration.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000398_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p><jats:sc>l<\/jats:sc>-Arginine pre-treatment prevented the antidepressant-like effect of ketamine in the FST, as well as a ketamine-induced increase in cGMP levels in the frontal cortex and hippocampus of FSL rats. Ketamine reduced cNOS activity only in the hippocampus, and this effect was not reversed by<jats:sc>l<\/jats:sc>-arginine.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000398_abs4\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>Both the behavioural and molecular results from this study indicate an involvement for the NO signalling pathway in the antidepressant action of ketamine. Although not easily interpretable, these findings broaden our knowledge of effects of ketamine on the NO system.<\/jats:p><\/jats:sec>","DOI":"10.1017\/neu.2014.39","type":"journal-article","created":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T07:58:29Z","timestamp":1418198309000},"page":"90-96","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":42,"title":["Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression"],"prefix":"10.1017","volume":"27","author":[{"given":"Nico","family":"Liebenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e2mia","family":"Joca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregers","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,12,10]]},"reference":[{"key":"S0924270814000398_ref19","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2012.0276"},{"key":"S0924270814000398_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(02)02017-5"},{"key":"S0924270814000398_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2010.11.027"},{"key":"S0924270814000398_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.03.030"},{"key":"S0924270814000398_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000035"},{"key":"S0924270814000398_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2013.11.003"},{"key":"S0924270814000398_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00655-9"},{"key":"S0924270814000398_ref29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/mol.59.1.24","article-title":"Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme","volume":"59","author":"Demady","year":"2001","journal-title":"Mol Pharmacol"},{"key":"S0924270814000398_ref35","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990241"},{"key":"S0924270814000398_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.08.010"},{"key":"S0924270814000398_ref15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1742-7843.2012.00877.x","article-title":"Inhibition of neuronal nitric oxide synthase and soluble guanylate cyclase prevents depression-like behaviour in rats exposed to chronic unpredictable mild stress","volume":"111","author":"Yazir","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"S0924270814000398_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"S0924270814000398_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(00)00164-6"},{"key":"S0924270814000398_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.07.046"},{"key":"S0924270814000398_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00191-0"},{"key":"S0924270814000398_ref7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287"},{"key":"S0924270814000398_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2003.09.015"},{"key":"S0924270814000398_ref26","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005397"},{"key":"S0924270814000398_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2012.12.003"},{"key":"S0924270814000398_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.05.028"},{"key":"S0924270814000398_ref33","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J Neurosci: the Official Journal of the Society for Neuroscience"},{"key":"S0924270814000398_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2011.07.024"},{"key":"S0924270814000398_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2005.03.015"},{"key":"S0924270814000398_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.09.004"},{"key":"S0924270814000398_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(02)00084-0"},{"key":"S0924270814000398_ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0326-2"},{"key":"S0924270814000398_ref4","first-page":"1","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"10","author":"McGirr","year":"2014","journal-title":"Psychol Med"},{"key":"S0924270814000398_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.08.044"},{"key":"S0924270814000398_ref8","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.39.27467"},{"key":"S0924270814000398_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.07.027"},{"key":"S0924270814000398_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2014.03.004"},{"key":"S0924270814000398_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"S0924270814000398_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2013.05.010"},{"key":"S0924270814000398_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3664-5"},{"key":"S0924270814000398_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03738-1"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270814000398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T19:32:44Z","timestamp":1717615964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270814000398\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,10]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0924270814000398"],"URL":"https:\/\/doi.org\/10.1017\/neu.2014.39","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,10]]},"assertion":[{"value":"\u00a9 Scandinavian College of Neuropsychopharmacology 2014\u00a0This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}